Stephens Inc. AR Cuts Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Stephens Inc. AR decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 22.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,210 shares of the medical research company’s stock after selling 1,253 shares during the quarter. Stephens Inc. AR’s holdings in Charles River Laboratories International were worth $777,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Wolff Wiese Magana LLC purchased a new position in Charles River Laboratories International in the third quarter worth $32,000. Versant Capital Management Inc raised its position in Charles River Laboratories International by 1,071.4% in the fourth quarter. Versant Capital Management Inc now owns 164 shares of the medical research company’s stock worth $30,000 after acquiring an additional 150 shares in the last quarter. Assetmark Inc. raised its position in Charles River Laboratories International by 1,153.3% in the third quarter. Assetmark Inc. now owns 188 shares of the medical research company’s stock worth $37,000 after acquiring an additional 173 shares in the last quarter. Pinnacle Bancorp Inc. raised its position in Charles River Laboratories International by 52.0% in the fourth quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company’s stock worth $35,000 after acquiring an additional 65 shares in the last quarter. Finally, Wilmington Savings Fund Society FSB purchased a new position in Charles River Laboratories International in the third quarter worth $59,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Trading Down 0.5 %

Charles River Laboratories International stock opened at $153.20 on Friday. The stock has a market cap of $7.83 billion, a PE ratio of 19.17, a P/E/G ratio of 6.47 and a beta of 1.37. The stock has a 50-day moving average price of $177.23 and a 200 day moving average price of $191.71. Charles River Laboratories International, Inc. has a 52 week low of $150.79 and a 52 week high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61.

Analyst Upgrades and Downgrades

CRL has been the subject of several research analyst reports. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a research report on Friday, January 17th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price target for the company. in a research report on Monday, November 18th. JPMorgan Chase & Co. dropped their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Monday, February 3rd. Evercore ISI raised their price target on Charles River Laboratories International from $190.00 to $225.00 and gave the company an “in-line” rating in a research report on Thursday, November 7th. Finally, Bank of America dropped their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $200.79.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).